OS

Owen Smith

Director at Vianautis

United Kingdom

Overview

Work Experience

  • Partner

    2022 - Current

  • Investment Director

    2019 - 2022

    Investments in public and private advanced therapies companies, specialising in biotech investments. Contact: owen@4biocapital.com or op_smith@icloud.com

  • Principal

    2018 - 2019

  • Director

    2023

  • Director

    2020

    SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration.

  • Director

    2019

  • Board Member

    2018 - 2024

  • Board Observer

    2017 - 2017

    LogicBio Therapeutics is a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases. The company’s GeneRide technology hitches a therapeutic transgene to a native promoter without disrupting its normal function in the host genome, enabling permanent expression of a functional version of a missing or faulty gene. Thus − with just a single treatment early in a child’s life – LogicBio can potentially deliver a life-long cure for a devastating disease.

  • Board Observer

    2016 - 2017

    Depixus is developing unique technology to sequence epigenetic modifications to native RNA and DNA at single molecule level.

  • Life Sciences VC

    2016 - 2017

    Investment firm focused on early, mid, and late-stage biotech and pharma companies (private and public). Investments involved with: Autolus, Depixus, Verona, OptiKira, LogicBio, Atox Bio

  • Life Sciences VC

    2015 - 2016

    Investments worked on: Cequr, Apitope, Reneuron

  • Executive

    2013 - 2015

  • Associate

    2010 - 2013

Relevant Websites